Other
CN
EU
USA
Description: Venetoclax (formerly known as ABT-199 or GDC-0199; Venclexta) is a potent, selective and orally bioavailable small molecule inhibitor of the anti-apoptotic protein BCL-2 (B-cell lymphoma-2) with Ki of<0.01 nM. On April 11, 2016, the FDA approved venetoclax for use in patients with chronic lymphocytic leukemia (CLL) who have 17p deletion (deletion located on the chromosome 17 short arm) and who have been treated with at least one prior therapy. The mechanism of action of venetoclax is to mimic BH3 (the native ligand of BCL-2) and act as a BCL-2 inhibitor. It blocks the anti-apoptotic BCL-2 protein, leading to programmed cell death of CLL cells.
References: Haematologica. 2017 Apr;102(4):755-764; Souers AJ, et al. Nat Med, 2013, 19(2), 202-208.
Publications Citing Use of InvivoChem Venetoclax (ABT-199; GDC-0199):
[1] Seiller et al. Cell Death and Disease ( 2020) 11:316.
[2] VCP/p97 inhibitor for the treatment of cancer. WO 2021/231323 A1
Product Catalog 2022
Guide to Product Handling
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
Lot#: V000101,Purity ≥98%
COA
MSDS
NMR
HPLC
Lot#: V000102,Purity ≥98%
Animals with xenograft lymphomas were treated with Torin1 and/or BCL-2 inhibitor, ABT-199. Haematologica. 2017 Apr;102(4):755-764.
BH3 profiling predicts sensitivity to TORKi treatment. Haematologica. 2017;102(4):755-764.
ABT-199 response in human T-ALL cell lines.Blood. 2014, 124(25):3738-47.
ABT-199 sensitivity in a mouse xenograft model of the T-ALL cell line LOUCY. Blood. 2014 ;124(25):3738-47.
BCL-2 expression and ABT-199 sensitivity in the Lck-Lmo2 transgenic mouse model. Blood. 2014 Dec 11;124(25):3738-47.
ABT-199 sensitivity in primary human T-ALL patient samples. Blood. 2014 Dec 11;124(25):3738-47.
ABT-199 in combination with chemotherapeutic agents in human T-ALL cell lines. Blood. 2014 Dec 11;124(25):3738-47.